Pretransplant immunotherapy increases acute rejection yet improves survival outcome of HCC patients with MVI post-liver transplantation

Xinjun Lu,Qi Zhu,Junfeng Cai,Zuozhong Yang,Guangxiang Gu,Li Pang,Mingye Su,Fapeng Zhang,Haoming Lin,Wenrui Wu,Leibo Xu,Chao Liu

DOI: https://doi.org/10.1007/s00262-024-03853-9

IF: 6.63

2024-11-13

Cancer Immunology Immunotherapy

Abstract:Immune checkpoint inhibitor (ICI)-based immunotherapy has emerged as the most promising strategy for hepatocellular carcinoma (HCC) downstaging prior to liver transplantation (LT). However, further evidence is required to assess the feasibility and safety of pretransplant ICI exposure. We retrospective analyzed 159 HCC patients who underwent LT at our institution from June 2019 to December 2023, and 39 recipients (39/159, 24.5%) received pretransplant ICI therapy. The perioperative acute rejection rate and rejection-related mortality rate in the ICI group were 23.1% (9/39) and 12.8% (5/39), respectively, which were significantly higher than those in the non-ICI group, at 5% (6/120, P = 0.002) and 0% (0/120, P = 0.001). There was no significant difference in the 90-day post-transplant overall survival (OS) ( P = 0.447) and recurrence-free survival (RFS) ( P = 0.723) between these two groups. We found 37.1% (59/159) recipients were found to have microvascular invasion (MVI), no matter whether the HCC tumor is within Milan criteria or not. Notably, though MVI was identified as a risk factor for the LT recipients, pretransplant ICI exposure appeared to be a protective factor for HCC patients with MVI which benefits its overall survival. Besides, the RFS and OS in the ICI exposure recipients with MVI were comparable to the non-ICI exposure recipients without MVI. However, no synergistic anti-tumor effects were observed with pretransplant ICI immunotherapy when combined with locoregional of TACE, HAIC, RFA and systematic of lenvatinib or sorafenib downstaging treatments, nor with post-transplant adjuvant of systematic or FOLFOX chemotherapy. Further comprehensive studies are needed to balance the dual natural effects of immunotherapy by optimizing downstaging protocols and patient selection to reduce acute rejection and improve long-term survival.

oncology,immunology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to evaluate the safety and effectiveness of immune checkpoint inhibitor (ICI) treatment in patients with hepatocellular carcinoma (HCC) before liver transplantation (LT). Specifically, the study focuses on the following aspects:

1. **Risk of acute rejection**: Evaluate whether ICI treatment increases the risk of acute rejection (AR) after liver transplantation and its related mortality.
2. **Impact on survival outcomes**: Explore the impact of ICI treatment on the overall survival (OS) and recurrence - free survival (RFS) within 90 days after transplantation in HCC patients.
3. **Impact on patients with microvascular invasion (MVI)**: Analyze the impact of ICI treatment on the long - term survival outcomes of HCC patients with MVI, especially the survival advantage compared with non - MVI patients who did not receive ICI treatment.
4. **Effect of combination therapy**: Evaluate the combined effect of ICI treatment with locoregional treatments (such as TACE, HAIC, RFA), systemic treatments (such as lenvatinib or sorafenib), and adjuvant chemotherapy after transplantation (such as FOLFOX), and whether it can produce a synergistic anti - tumor effect.

Through a retrospective analysis of the clinical data of 159 HCC patients, the study found that:

- **Acute rejection**: The acute rejection rate in the ICI group was significantly higher than that in the non - ICI group (23.1% vs 5%, P = 0.002), and the AR - related mortality also increased significantly (12.8% vs 0%, P = 0.001).
- **Short - term survival outcomes**: Within 90 days, there were no significant differences in RFS and OS between the ICI group and the non - ICI group (P = 0.723 and P = 0.447).
- **Patients with MVI**: Although MVI is an independent risk factor for survival after transplantation, ICI treatment significantly improved the OS of patients with MVI (P = 0.018). In addition, the RFS and OS of MVI patients treated with ICI were comparable to those of non - MVI patients not treated with ICI (P > 0.05).
- **Combination therapy**: The combined use of ICI treatment with locoregional treatment, systemic treatment, or adjuvant chemotherapy after transplantation did not show a synergistic anti - tumor effect.

In summary, this study aims to balance how to reduce the risk of acute rejection while improving the survival rate of HCC patients with ICI treatment, and optimize the treatment plan to improve long - term survival outcomes.